- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01576731
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) (RAL-PEP)
Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir
As a measure of secondary prophylaxis, and with the final objective of avoiding the infection, it has been suggested to use antiretroviral therapy. This is known as post-exposure prophylaxis (PEP).
Although there are different recommendations, almost every guideline recommend using 3 drugs as PEP both in USA and Europe.
Toxicity is one of the main limitations of PEP. Side effects during PEP are very usual, are attributed mainly to PI and are the main reasons for poor adherence or lost of follow-up.
A current standard regimen is AZT+3TC (Combivir®) or tenofovir+emtricitabine (Truvada®) plus the PI lopinavir/r. Toxicity associated with this regimens are high (31-85% of cases),with a high tolerability, a integrase inhibitor (raltegravir)could be an adequate drug for PEP.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08036
- Hospital Clinic of Barcelona
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Potentially sexual exposition to HIV
Exclusion Criteria:
- Pregnancy
- Source case with antiretroviral resistances
- any treatment contraindicated with the drugs of study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Tenofovir + emtricitabine + lopinavir/r
Standard postexposure prophylaxis combination
|
Combination drug
|
Experimental: Tenofovir + Emtricitabine + Raltegravir
new postexposure prophylaxis combination
|
Combination drug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients dropping out before the 28 days of postexposure prophylaxis
Time Frame: 28 days
|
Proportion of patients droppping out before the 28 days of postexposure prophylaxis considering death, lost to folow-up and stopping or changing treatment for any reason
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Felipe Garcia, PhD, Consultant senior
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Integrase Inhibitors
- Integrase Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Tenofovir
- Emtricitabine
- Raltegravir Potassium
- Lopinavir
Other Study ID Numbers
- 2011-003799-35
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on Tenofovir, Emtricitabine, Lopinavir/r
-
AbbottMerck Sharp & Dohme LLCCompletedHuman Immunodeficiency Virus InfectionUnited States, Canada, France, Italy, Poland, Puerto Rico, Spain
-
Hospital Clinic of BarcelonaCompleted
-
ANRS, Emerging Infectious DiseasesGilead Sciences; Janssen PharmaceuticaCompletedHIV Infections | HIVBurkina Faso, Cameroon, Senegal
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV InfectionsPeru, Brazil, South Africa, Uganda, Botswana, Haiti, Zambia, Zimbabwe
-
Fundacion Clinic per a la Recerca BiomédicaCompleted
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical...TerminatedHIV InfectionsUnited States, Peru
-
University of California, San FranciscoMerck Sharp & Dohme LLC; Gilead Sciences; National Institutes of Health (NIH); ...Completed
-
French National Agency for Research on AIDS and...Merck Sharp & Dohme LLC; Gilead Sciences; Institut de Médecine et d'Epidémiologie...CompletedHIV InfectionsSenegal, Cameroon
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | AIDS-Related Opportunistic InfectionsUnited States, Puerto Rico, South Africa
-
Technical University of MunichGilead Sciences; MUC Research GmbHCompletedInsulin ResistanceGermany